COMMUNIQUÉS West-GlobeNewswire

Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
02/09/2026
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients Reports an Apnea-Hypopnea Index (AHI) responder [...]
Nyxoah Annonce que l'Étude Pivot Américaine ACCCESS Atteint ses Critères Principaux de Sécurité et d'Efficacité chez les Patients Présentant un Collapsus Concentrique Complet
02/09/2026
INFORMATIONS RÉGLEMENTÉES INFORMATIONS PRIVILÉGIÉES Nyxoah Annonce que l'Étude Pivot Américaine ACCCESS Atteint ses Critères Principaux de Sécurité et d'Efficacité chez les Patients Présentant un Collapsus Concentrique [...]
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
02/09/2026
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohort Topline results of NATiV3 expected in Q4 2026 September investor [...]
Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH
02/09/2026
Le dernier patient de l’étude NATiV3 a désormais réalisé sa dernière visite à 72 semaines, portant à 1 009 le nombre de patients inclus dans la cohorte principale et à 410 celui de la cohorte exploratoire. Les résultats [...]
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
02/09/2026
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Aura Biosciences to Participate in Upcoming Investor Conference
02/09/2026
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, [...]
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
02/09/2026
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09/2026
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant [...]
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
02/09/2026
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, [...]
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
02/09/2026
Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI) NOVATO, Calif., Sept. 02, [...]
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
02/09/2026
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers [...]
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
02/09/2026
Anavex Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all Three Core Indications Forward NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- [...]
Cytokinetics to Participate in September Investor Conferences
02/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor [...]
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
02/09/2026
WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Scientist Home Future Health Reports Second Quarter 2026 Financial Results
02/09/2026
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Scientist Home Future Health LTD (OTCID: SHFH ) today reported financial results for the three and six months ended June 30, 2026. Key Financial Highlights: Operating Results [...]
Biocodex Microbiota Foundation invites Canadian academics and scientists to apply for €35,000 ($55,000 CAD based on current exchange rate) research grant to advance microbiota research in human health & disease
02/09/2026
MONTREAL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation, an organization founded by Biocodex and dedicated to supporting scientific projects that explore the microbiome, is inviting grant [...]
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09/2026
NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09/2026
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09/2026
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]

Pages